Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 941–950 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 941
- Medicine slug
- mercaptopurine
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 6
- Source count
- 6
- Agreement rate
- 1
- Recorded readings
19%
- Numeric value
- 19
- Unit
- %
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3b5b8b0-bc5c-4ce9-bbdc-febba60c2658 (opens source in a new tab)
Mercaptopurine label
Version not recorded · Effective date not recorded
Plasma protein binding averages 19% over the concentration range 10 to 50 mcg/mL (a concentration only achieved by intravenous administration of mercaptopurine at doses exceeding 5 to 10 mg/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7309808-5ae8-4a55-90e3-3992ace0da62 (opens source in a new tab)
Mercaptopurine label
Version not recorded · Effective date not recorded
Plasma protein binding averages 19% over the concentration range 10 to 50 mcg/mL (a concentration only achieved by intravenous administration of mercaptopurine at doses exceeding 5 to 10 mg/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c6fc66b-522f-499d-961a-cde6ca0ec2e5 (opens source in a new tab)
Mercaptopurine label
Version not recorded · Effective date not recorded
Plasma protein binding averages 19% over the concentration range 10 to 50 mcg/L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25b39be7-fe1e-efe6-e063-6294a90a6e8d (opens source in a new tab)
Mercaptopurine label
Version not recorded · Effective date not recorded
Plasma protein binding averages 19% over the concentration range 10 to 50 mcg/L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a366cf3-91f0-4aa4-8f34-a7a27cad8f15 (opens source in a new tab)
Mercaptopurine label
Version not recorded · Effective date not recorded
Plasma protein binding averages 19% over the concentration range 10 to 50 mcg/L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4bae5ffb-a535-3fa0-e063-6294a90aa90a (opens source in a new tab)
Mercaptopurine label
Version not recorded · Effective date not recorded
Plasma protein binding averages 19% over the concentration range 10 to 50 mcg/mL (a concentration only achieved by intravenous administration of mercaptopurine at doses exceeding 5 to 10 mg/kg).
Projected row 942
- Medicine slug
- mercaptopurine
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 6
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
0.9 L/kg
- Numeric value
- 0.9
- Unit
- L/kg
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c6fc66b-522f-499d-961a-cde6ca0ec2e5 (opens source in a new tab)
Mercaptopurine label
Version not recorded · Effective date not recorded
Distribution The volume of distribution exceeds total body water with a mean volume of distribution of approximately 0.9 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25b39be7-fe1e-efe6-e063-6294a90a6e8d (opens source in a new tab)
Mercaptopurine label
Version not recorded · Effective date not recorded
Distribution The volume of distribution exceeds total body water with a mean volume of distribution of approximately 0.9 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a366cf3-91f0-4aa4-8f34-a7a27cad8f15 (opens source in a new tab)
Mercaptopurine label
Version not recorded · Effective date not recorded
Distribution The volume of distribution exceeds total body water with a mean volume of distribution of approximately 0.9 L/kg.
Projected row 943
- Medicine slug
- meropenem
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 25
- Source count
- 25
- Agreement rate
- 1
- Recorded readings
1 hour
- Numeric value
- 1
- Unit
- hours
- Source records
- 25
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 25 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf1d3433-9e3f-40a0-8bff-c8ceaa8bab7c (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
1.1 (2 hours) 0.2 to 2.8 40 mg/kg 4 5 3.3 (3 hours) 0.9 to 6.5 CSF (uninflamed) 1 4 0.2 (2 hours) 0.1 to 0.3 Elimination In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca5f501c-6520-4d09-aae2-4f5db74d468f (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
luid 3. in pediatric patients of age 5 months to 8 years 4. in pediatric patients of age 1 month to 15 years Elimination In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d54fdbad-ca93-467c-92d7-c1bd88f3bbe3 (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
1.1 (2 hours) 0.2 to 2.8 40 mg/kg 4 5 3.3 (3 hours) 0.9 to 6.5 CSF (uninflamed) 1 4 0.2 (2 hours) 0.1 to 0.3 Elimination In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74ff19b5-6156-4a27-affb-744b0ce1aeec (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
15 years 8 5 1.1 (2 hours) 3.3 (3 hours) 0.2 to 2.8 0.9 to 6.5 CSF (uninflamed) 1 4 0.2 (2 hours) 0.1 to 0.3 Elimination In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b0075b72-c3cc-f844-e053-2a95a90a417f (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
nths to 15 years. 8 5 1.1 (2 hours) 3.3 (3 hours) 0.2-2.8 0.9-6.5 CSF (uninflamed) 1 4 0.2 (2 hours) 0.1-0.3 Elimination In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0d37e43b-ff8d-495d-b9af-4fd5fce53d56 (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
month to 15 years 8 5 1.1 (2 hours) 3.3 (3 hours) 0.2-2.8 0.9-6.5 CSF (uninflamed) 1 4 0.2 (2 hours) 0.1-0.3 Elimination In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:240325ba-47a8-4ad1-bcab-6772069ee790 (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
of age) 8 5 1.1 (2 hours) 3.3 (3 hours) 0.2 to 2.8 0.9 to 6.5 CSF (uninflamed) 1 4 0.2 (2 hours) 0.1 to 0.3 Elimination In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06d84c55-94ff-46e5-8477-b8881c12eb0a (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
patients of age 1 month to 15 years 5 3.3 (3 hours) 0.9 to 6.5 CSF (uninflamed) 1 4 0.2 (2 hours) 0.1 to 0.3 Elimination In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8848f4a-bca9-4978-b0a1-38483fd4d639 (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
mg/kg 4 8 5 1.1 (2 hours) 3.3 (3 hours) 0.2 to 2.8 0.9 to 6.5 CSF (uninflamed) 1 4 0.2 (2 hours) 0.1 to 0.3 Elimination In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a68d899-2678-43a9-a9c1-ef8f916b562f (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
mg/kg 4 8 5 1.1 (2 hours) 3.3 (3 hours) 0.2 to 2.8 0.9 to 6.5 CSF (uninflamed) 1 4 0.2 (2 hours) 0.1 to 0.3 Elimination In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a2a545e-b336-416a-be73-9e0a7ccf6177 (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
ster fluid in pediatric patients of age 5 months to 8 years in pediatric patients of age 1 month to 15 years Elimination In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9b6555f-20a1-4415-bb80-3d034cfab95b (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
15 years 8 5 1.1 (2 hours) 3.3 (3 hours) 0.2 to 2.8 0.9 to 6.5 CSF (uninflamed) 1 4 0.2 (2 hours) 0.1 to 0.3 Elimination In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e4e2c0c-df54-4229-ab90-fa671ecedd57 (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
fluid 3 in pediatric patients of age 5 months to 8 years 4 in pediatric patients of age 1 month to 15 years Elimination In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:31dd2160-7dbd-51fa-e054-00144ff88e88 (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
month to 15 years 8 5 1.1 (2 hours) 3.3 (3 hours) 0.2-2.8 0.9-6.5 CSF (uninflamed) 1 4 0.2 (2 hours) 0.1-0.3 Elimination In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5154b6f-bca8-4f1e-907b-48ea34caf483 (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
5 years (Meropenem for Injection is not approved for use in pediatric patients younger than 3 months of age) Elimination In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f9591ed-3a6c-422e-b1be-7b3e4fe5bf3c (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
month to 15 years 8 5 1.1 (2 hours) 3.3 (3 hours) 0.2–2.8 0.9–6.5 CSF (uninflamed) 1 4 0.2 (2 hours) 0.1–0.3 Elimination In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35466216-55ed-4836-8cbc-c8aafb079dae (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
luid 3. in pediatric patients of age 5 months to 8 years 4. in pediatric patients of age 1 month to 15 years Elimination In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:092ebd9b-77a0-4877-afc3-dd8211730f71 (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
15 years 8 5 1.1 (2 hours) 3.3 (3 hours) 0.2 to 2.8 0.9 to 6.5 CSF (uninflamed) 1 4 0.2 (2 hours) 0.1 to 0.3 Elimination In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58e165b7-e230-4459-abf9-06d5ca1dd7b2 (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
luid 3. in pediatric patients of age 5 months to 8 years 4. in pediatric patients of age 1 month to 15 years Elimination In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a456013b-b20e-4b29-b2f9-06f18f1ea6bd (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
luid 3. in pediatric patients of age 5 months to 8 years 4. in pediatric patients of age 1 month to 15 years Elimination In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6520ae3d-e149-499c-8152-36f6ab861662 (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
15 years 8 5 1.1 (2 hours) 3.3 (3 hours) 0.2 to 2.8 0.9 to 6.5 CSF (uninflamed) 1 4 0.2 (2 hours) 0.1 to 0.3 Elimination In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6902fee1-6022-4145-a79a-4680ad1fb1e8 (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
5 years (Meropenem for Injection is not approved for use in pediatric patients younger than 3 months of age) Elimination In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:185181e3-c004-4d61-b992-5df94fe57a90 (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
mg/kg 4 8 5 1.1 (2 hours) 3.3 (3 hours) 0.2 to 2.8 0.9 to 6.5 CSF (uninflamed) 1 4 0.2 (2 hours) 0.1 to 0.3 Elimination In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12714f80-d6e5-4453-b66c-62f57c16ddfc (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
mg/kg 4 8 5 1.1 (2 hours) 3.3 (3 hours) 0.2 to 2.8 0.9 to 6.5 CSF (uninflamed) 1 4 0.2 (2 hours) 0.1 to 0.3 Elimination In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1122310-c3ed-42f1-b189-301c221ff1f0 (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
ster fluid in pediatric patients of age 5 months to 8 years in pediatric patients of age 1 month to 15 years Elimination In subjects with normal renal function, the elimination half-life of meropenem is approximately 1 hour.
Projected row 944
- Medicine slug
- meropenem
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 25
- Source count
- 25
- Agreement rate
- 1
- Recorded readings
2%
- Numeric value
- 2
- Unit
- %
- Source records
- 25
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 25 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf1d3433-9e3f-40a0-8bff-c8ceaa8bab7c (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
Distribution The plasma protein binding of meropenem is approximately 2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca5f501c-6520-4d09-aae2-4f5db74d468f (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
Distribution The plasma protein binding of meropenem is approximately 2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d54fdbad-ca93-467c-92d7-c1bd88f3bbe3 (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
Distribution The plasma protein binding of meropenem is approximately 2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74ff19b5-6156-4a27-affb-744b0ce1aeec (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
Distribution The plasma protein binding of meropenem is approximately 2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b0075b72-c3cc-f844-e053-2a95a90a417f (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
Distribution The plasma protein binding of meropenem is approximately 2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0d37e43b-ff8d-495d-b9af-4fd5fce53d56 (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
Distribution The plasma protein binding of meropenem is approximately 2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:240325ba-47a8-4ad1-bcab-6772069ee790 (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
Distribution The plasma protein binding of meropenem is approximately 2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06d84c55-94ff-46e5-8477-b8881c12eb0a (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
Distribution The plasma protein binding of meropenem is approximately 2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8848f4a-bca9-4978-b0a1-38483fd4d639 (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
Distribution The plasma protein binding of meropenem is approximately 2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a68d899-2678-43a9-a9c1-ef8f916b562f (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
Distribution The plasma protein binding of meropenem is approximately 2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a2a545e-b336-416a-be73-9e0a7ccf6177 (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
Distribution The plasma protein binding of meropenem is approximately 2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9b6555f-20a1-4415-bb80-3d034cfab95b (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
Distribution The plasma protein binding of meropenem is approximately 2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e4e2c0c-df54-4229-ab90-fa671ecedd57 (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
Distribution The plasma protein binding of meropenem is approximately 2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:31dd2160-7dbd-51fa-e054-00144ff88e88 (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
Distribution The plasma protein binding of meropenem is approximately 2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5154b6f-bca8-4f1e-907b-48ea34caf483 (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
Distribution The plasma protein binding of meropenem is approximately 2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f9591ed-3a6c-422e-b1be-7b3e4fe5bf3c (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
Distribution The plasma protein binding of meropenem is approximately 2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35466216-55ed-4836-8cbc-c8aafb079dae (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
Distribution The plasma protein binding of meropenem is approximately 2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:092ebd9b-77a0-4877-afc3-dd8211730f71 (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
Distribution The plasma protein binding of meropenem is approximately 2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58e165b7-e230-4459-abf9-06d5ca1dd7b2 (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
Distribution The plasma protein binding of meropenem is approximately 2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a456013b-b20e-4b29-b2f9-06f18f1ea6bd (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
Distribution The plasma protein binding of meropenem is approximately 2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6520ae3d-e149-499c-8152-36f6ab861662 (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
Distribution The plasma protein binding of meropenem is approximately 2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6902fee1-6022-4145-a79a-4680ad1fb1e8 (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
Distribution The plasma protein binding of meropenem is approximately 2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:185181e3-c004-4d61-b992-5df94fe57a90 (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
Distribution The plasma protein binding of meropenem is approximately 2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12714f80-d6e5-4453-b66c-62f57c16ddfc (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
Distribution The plasma protein binding of meropenem is approximately 2%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1122310-c3ed-42f1-b189-301c221ff1f0 (opens source in a new tab)
Meropenem label
Version not recorded · Effective date not recorded
Distribution The plasma protein binding of meropenem is approximately 2%.
Projected row 945
- Medicine slug
- mesalamine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 61
- Source count
- 10
- Agreement rate
- 1
- Recorded readings
5 hours
- Numeric value
- 5
- Unit
- hours
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ac78fa0-60a8-48dd-abc4-a487f98039a2 (opens source in a new tab)
Mesalamine label
Version not recorded · Effective date not recorded
Elimination In patients with ulcerative proctitis treated with mesalamine 500 mg as a rectal suppository every 8 hours for 6 days, the mean elimination half-life was 5 hours (CV=73%) for 5-ASA and 5 hours (CV=63%) for N-acetyl-5-ASA, the active metabolite, following the initial dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de981df1-747a-480d-a866-e72332a1544d (opens source in a new tab)
Mesalamine label
Version not recorded · Effective date not recorded
Elimination In patients with ulcerative proctitis treated with mesalamine 500 mg as a rectal suppository every 8 hours for 6 days, the mean elimination half-life was 5 hours (CV=73%) for 5-ASA and 5 hours (CV=63%) for N-acetyl-5-ASA, the active metabolite, following the initial dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87de237c-febb-42ca-b2a4-b444396f8640 (opens source in a new tab)
Mesalamine label
Version not recorded · Effective date not recorded
Elimination In patients with ulcerative proctitis treated with mesalamine 500 mg as a rectal suppository every 8 hours for 6 days, the mean elimination half-life was 5 hours (CV=73%) for 5-ASA and 5 hours (CV=63%) for N-acetyl-5-ASA, the active metabolite, following the initial dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efa9d039-ae1f-4cd6-98f2-e87a901dfaeb (opens source in a new tab)
Mesalamine label
Version not recorded · Effective date not recorded
Elimination In patients with ulcerative proctitis treated with mesalamine 500 mg as a rectal suppository every 8 hours for 6 days, the mean elimination half-life was 5 hours (CV=73%) for 5-ASA and 5 hours (CV=63%) for N-acetyl-5-ASA, the active metabolite, following the initial dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06792d20-d7e9-4b66-a4cb-cd0cf1a2db25 (opens source in a new tab)
Mesalamine label
Version not recorded · Effective date not recorded
Elimination In patients with ulcerative proctitis treated with mesalamine 500 mg as a rectal suppository every 8 hours for 6 days, the mean elimination half-life was 5 hours (CV=73%) for 5-ASA and 5 hours (CV=63%) for N-acetyl-5-ASA, the active metabolite, following the initial dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f458d574-7b5b-44f1-86be-8b18880dc67f (opens source in a new tab)
Mesalamine label
Version not recorded · Effective date not recorded
Elimination In patients with ulcerative proctitis treated with mesalamine 500 mg as a rectal suppository every 8 hours for 6 days, the mean elimination half-life was 5 hours (CV=73%) for 5-ASA and 5 hours (CV=63%) for N-acetyl-5-ASA, the active metabolite, following the initial dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89d91601-152b-4398-bebe-af1c023e9935 (opens source in a new tab)
Mesalamine label
Version not recorded · Effective date not recorded
Elimination In patients with ulcerative proctitis treated with mesalamine 500 mg as a rectal suppository every 8 hours for 6 days, the mean elimination half-life was 5 hours (CV=73%) for 5-ASA and 5 hours (CV=63%) for N-acetyl-5-ASA, the active metabolite, following the initial dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73317da3-cba0-4106-9e88-79b0e2f642af (opens source in a new tab)
Mesalamine label
Version not recorded · Effective date not recorded
Elimination In patients with ulcerative proctitis treated with mesalamine 500 mg as a rectal suppository every 8 hours for 6 days, the mean elimination half-life was 5 hours (CV=73%) for 5-ASA and 5 hours (CV=63%) for N-acetyl-5-ASA, the active metabolite, following the initial dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b48df65a-a717-479e-9122-8b0f1406c841 (opens source in a new tab)
Mesalamine label
Version not recorded · Effective date not recorded
Elimination In patients with ulcerative proctitis treated with mesalamine 500 mg as a rectal suppository every 8 hours for 6 days, the mean elimination half-life was 5 hours (CV=73%) for 5-ASA and 5 hours (CV=63%) for N-acetyl-5-ASA, the active metabolite, following the initial dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c26ae6cb-041b-4cfc-90ca-c4e1cb23458c (opens source in a new tab)
Mesalamine label
Version not recorded · Effective date not recorded
Elimination In patients with ulcerative proctitis treated with mesalamine 500 mg as a rectal suppository every 8 hours for 6 days, the mean elimination half-life was 5 hours (CV=73%) for 5-ASA and 5 hours (CV=63%) for N-acetyl-5-ASA, the active metabolite, following the initial dose.
Projected row 946
- Medicine slug
- mesalamine
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 61
- Source count
- 17
- Agreement rate
- 1
- Recorded readings
4 hours
- Numeric value
- 4
- Unit
- hours
- Source records
- 17
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 17 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e6978d0-01db-477d-a90f-27561777480f (opens source in a new tab)
Mesalamine label
Version not recorded · Effective date not recorded
After single and multiple doses of mesalamine extended-release capsules, peak plasma concentrations were observed at about 4 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8b93ea3-0367-4605-b87f-06c3812ff3b7 (opens source in a new tab)
Mesalamine label
Version not recorded · Effective date not recorded
After single and multiple doses of mesalamine extended-release capsules, peak plasma concentrations were observed at about 4 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e638681d-8fca-4bf8-a1fb-8e52357a64da (opens source in a new tab)
Mesalamine label
Version not recorded · Effective date not recorded
After single and multiple doses of mesalamine extended-release capsules, peak plasma concentrations were observed at about 4 hours post dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6c0fc76-644e-4301-9672-f432061e3d37 (opens source in a new tab)
Mesalamine label
Version not recorded · Effective date not recorded
After single and multiple doses of mesalamine extended-release capsules, peak plasma concentrations were observed at about 4 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d27a608-3ba1-4799-be38-c00fb08ce3ce (opens source in a new tab)
Mesalamine label
Version not recorded · Effective date not recorded
After single and multiple doses of mesalamine extended-release capsules, peak plasma concentrations were observed at about 4 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cfe4800f-868f-46fd-8b9a-977a91ae5fbe (opens source in a new tab)
Mesalamine label
Version not recorded · Effective date not recorded
After single and multiple doses of mesalamine extended-release capsules, peak plasma concentrations were observed at about 4 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef471372-8d9f-4d95-9371-44522c69058f (opens source in a new tab)
Mesalamine label
Version not recorded · Effective date not recorded
After single and multiple doses of mesalamine extended-release capsules, peak plasma concentrations were observed at about 4 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c4ffb68-3ca4-35cd-e063-6294a90ab929 (opens source in a new tab)
Mesalamine label
Version not recorded · Effective date not recorded
After single and multiple doses of mesalamine extended-release capsules, peak plasma concentrations were observed at about 4 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87d3d62d-2dc3-4e6f-be33-cabbca12e8f7 (opens source in a new tab)
Mesalamine label
Version not recorded · Effective date not recorded
After single and multiple doses of mesalamine, peak plasma concentrations were observed at about 4 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1ed6fcc-7fd4-4b8a-9ddb-e772ea930e9e (opens source in a new tab)
Mesalamine label
Version not recorded · Effective date not recorded
AUC: ↑ 29%) and delayed the median t max by approximately 4 hours compared to results in the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ef59b85-e5a5-479f-a1fe-e1cee4d87670 (opens source in a new tab)
Mesalamine label
Version not recorded · Effective date not recorded
After single and multiple doses of mesalamine, peak plasma concentrations were observed at about 4 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cd8493f7-91fd-4c2d-b3d7-c1301825586b (opens source in a new tab)
Mesalamine label
Version not recorded · Effective date not recorded
After single and multiple doses of mesalamine extended-release capsules, peak plasma concentrations were observed at about 4 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2657911-6f06-71fb-e053-2a95a90ae6f7 (opens source in a new tab)
Mesalamine label
Version not recorded · Effective date not recorded
After single and multiple doses of mesalamine extended-release capsules, peak plasma concentrations were observed at about 4 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6fd0a906-e1b5-4238-a79b-a195510ddc84 (opens source in a new tab)
Mesalamine label
Version not recorded · Effective date not recorded
AUC: ↑ 29%) and delayed the median t max by approximately 4 hours compared to results in the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43f69db3-81ac-4da4-a61f-fbba6299d9c2 (opens source in a new tab)
Mesalamine label
Version not recorded · Effective date not recorded
After single and multiple doses of mesalamine extended-release capsules, peak plasma concentrations were observed at about 4 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58503afe-b8d4-4710-a194-e3acd64ecf1f (opens source in a new tab)
Mesalamine label
Version not recorded · Effective date not recorded
After single and multiple doses of mesalamine extended-release capsules, peak plasma concentrations were observed at about 4 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7951139c-b271-45a4-b523-34b23800917b (opens source in a new tab)
Mesalamine label
Version not recorded · Effective date not recorded
After single and multiple doses of APRISO, peak plasma concentrations were observed at about 4 hours post-dose.
Projected row 947
- Medicine slug
- mesna
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 12
- Source count
- 11
- Agreement rate
- 1
- Recorded readings
58%
- Numeric value
- 58
- Unit
- %
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90d64539-33ad-47e8-9de7-17d6c5baaba4 (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
Oral bioavailability averaged 58% (range 45 to 71%) for free mesna and 89% (range 74 to 104%) for total mesna based on plasma AUC data from 8 healthy volunteers who received 1200 mg oral or intravenous doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a880160b-fa82-453a-a971-29ab897876a7 (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
Oral bioavailability averaged 58% (range 45 to 71%) for free mesna and 89% (range 74 to 104%) for total mesna based on plasma AUC data from 8 healthy volunteers who received 1200 mg oral or intravenous doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a2a526f-636b-7920-4261-6c626f612a2a (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
Oral bioavailability averaged 58% (range 45 to 71%) for free mesna and 89% (range 74 to 104%) for total mesna based on plasma AUC data from 8 healthy volunteers who received 1200 mg oral or intravenous doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe1683ef-0569-411e-8188-0499884632ad (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
Oral bioavailability averaged 58% (range 45 to 71%) for free mesna and 89% (range 74 to 104%) for total mesna based on plasma AUC data from 8 healthy volunteers who received 1200 mg oral or intravenous doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e8eebc3-ea75-4c57-bfe1-2c5dc2c37806 (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
Oral bioavailability averaged 58% (range 45 to 71%) for free mesna and 89% (range 74 to 104%) for total mesna based on plasma AUC data from 8 healthy volunteers who received 1200 mg oral or intravenous doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7af968c-05cf-4438-94ba-96a2baf9c367 (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
Oral bioavailability averaged 58% (range 45 to 71%) for free mesna and 89% (range 74 to 104%) for total mesna based on plasma AUC data from 8 healthy volunteers who received 1200 mg oral or intravenous doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49fdfbc3-69f8-4706-9d11-bf60e4e7811b (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
Oral bioavailability averaged 58% (range 45 to 71%) for free mesna and 89% (range 74 to 104%) for total mesna based on plasma AUC data from 8 healthy volunteers who received 1200 mg oral or intravenous doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1dd69e84-616d-fb77-e063-6394a90af2f4 (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
Oral bioavailability averaged 58% (range 45 to 71%) for free mesna and 89% (range 74 to 104%) for total mesna based on plasma AUC data from 8 healthy volunteers who received 1200 mg oral or intravenous doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef161ede-0451-43c8-b0e5-cb108b138e38 (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
Oral bioavailability averaged 58% (range 45 to 71%) for free mesna and 89% (range 74 to 104%) for total mesna based on plasma AUC data from 8 healthy volunteers who received 1,200 mg oral or intravenous doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49e9c804-9e88-4774-8faf-35bd61b3a8e9 (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
Oral bioavailability averaged 58% (range 45 to 71%) for free mesna and 89% (range 74 to 104%) for total mesna based on plasma AUC data from 8 healthy volunteers who received 1,200 mg oral or intravenous doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a51ffdb-f59f-4e02-b3c4-f3457ab7b514 (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
Oral bioavailability averaged 58% (range 45 to 71%) for free mesna and 89% (range 74 to 104%) for total mesna based on plasma AUC data from 8 healthy volunteers who received 1200 mg oral or intravenous doses.
Projected row 948
- Medicine slug
- mesna
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 12
- Source count
- 11
- Agreement rate
- 1
- Recorded readings
1.5 to 4 hours
- Numeric value
- 1.5
- Unit
- hours
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90d64539-33ad-47e8-9de7-17d6c5baaba4 (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following oral administration, peak plasma concentrations were reached within 1.5 to 4 hours and 3 to 7 hours for free mesna and total mesna (mesna plus dimesna and mixed disulfides), respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a880160b-fa82-453a-a971-29ab897876a7 (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following oral administration, peak plasma concentrations were reached within 1.5 to 4 hours and 3 to 7 hours for free mesna and total mesna (mesna plus dimesna and mixed disulfides), respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a2a526f-636b-7920-4261-6c626f612a2a (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following oral administration, peak plasma concentrations were reached within 1.5 to 4 hours and 3 to 7 hours for free mesna and total mesna (mesna plus dimesna and mixed disulfides), respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe1683ef-0569-411e-8188-0499884632ad (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following oral administration, peak plasma concentrations were reached within 1.5 to 4 hours and 3 to 7 hours for free mesna and total mesna (mesna plus dimesna and mixed disulfides), respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e8eebc3-ea75-4c57-bfe1-2c5dc2c37806 (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following oral administration, peak plasma concentrations were reached within 1.5 to 4 hours and 3 to 7 hours for free mesna and total mesna (mesna plus dimesna and mixed disulfides), respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7af968c-05cf-4438-94ba-96a2baf9c367 (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following oral administration, peak plasma concentrations were reached within 1.5 to 4 hours and 3 to 7 hours for free mesna and total mesna (mesna plus dimesna and mixed disulfides), respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49fdfbc3-69f8-4706-9d11-bf60e4e7811b (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following oral administration, peak plasma concentrations were reached within 1.5 to 4 hours and 3 to 7 hours for free mesna and total mesna (mesna plus dimesna and mixed disulfides), respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1dd69e84-616d-fb77-e063-6394a90af2f4 (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following oral administration, peak plasma concentrations were reached within 1.5 to 4 hours and 3 to 7 hours for free mesna and total mesna (mesna plus dimesna and mixed disulfides), respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef161ede-0451-43c8-b0e5-cb108b138e38 (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following oral administration, peak plasma concentrations were reached within 1.5 to 4 hours and 3 to 7 hours for free mesna and total mesna (mesna plus dimesna and mixed disulfides), respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49e9c804-9e88-4774-8faf-35bd61b3a8e9 (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following oral administration, peak plasma concentrations were reached within 1.5 to 4 hours and 3 to 7 hours for free mesna and total mesna (mesna plus dimesna and mixed disulfides), respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a51ffdb-f59f-4e02-b3c4-f3457ab7b514 (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following oral administration, peak plasma concentrations were reached within 1.5 to 4 hours and 3 to 7 hours for free mesna and total mesna (mesna plus dimesna and mixed disulfides), respectively.
Projected row 949
- Medicine slug
- mesna
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 12
- Source count
- 12
- Agreement rate
- 1
- Recorded readings
0.652 ± 0.242 L/kg
- Numeric value
- 0.652
- Unit
- L/kg
- Source records
- 12
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 12 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8012b97b-4e39-451f-8e04-542d196e8bc6 (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Distribution Mean apparent volume of distribution (V d ) for mesna is 0.652 ± 0.242 L/kg after intravenous administration which suggests distribution to total body water (plasma, extracellular fluid, and intracellular water).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90d64539-33ad-47e8-9de7-17d6c5baaba4 (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
Distribution Mean apparent volume of distribution (V d ) for mesna is 0.652 ± 0.242 L/kg after intravenous administration which suggests distribution to total body water (plasma, extracellular fluid, and intracellular water).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a880160b-fa82-453a-a971-29ab897876a7 (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
Distribution Mean apparent volume of distribution (V d ) for mesna is 0.652 ± 0.242 L/kg after intravenous administration which suggests distribution to total body water (plasma, extracellular fluid, and intracellular water).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a2a526f-636b-7920-4261-6c626f612a2a (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
Distribution Mean apparent volume of distribution (V d ) for mesna is 0.652 ± 0.242 L/kg after intravenous administration which suggests distribution to total body water (plasma, extracellular fluid, and intracellular water).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe1683ef-0569-411e-8188-0499884632ad (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
Distribution Mean apparent volume of distribution (V d ) for mesna is 0.652 ± 0.242 L/kg after intravenous administration which suggests distribution to total body water (plasma, extracellular fluid, and intracellular water).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e8eebc3-ea75-4c57-bfe1-2c5dc2c37806 (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
Distribution Mean apparent volume of distribution (V d ) for mesna is 0.652 ± 0.242 L/kg after intravenous administration which suggests distribution to total body water (plasma, extracellular fluid, and intracellular water).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7af968c-05cf-4438-94ba-96a2baf9c367 (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
Distribution Mean apparent volume of distribution (V d ) for mesna is 0.652 ± 0.242 L/kg after intravenous administration which suggests distribution to total body water (plasma, extracellular fluid, and intracellular water).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49fdfbc3-69f8-4706-9d11-bf60e4e7811b (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
Distribution Mean apparent volume of distribution (V d ) for mesna is 0.652 ± 0.242 L/kg after intravenous administration which suggests distribution to total body water (plasma, extracellular fluid, and intracellular water).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1dd69e84-616d-fb77-e063-6394a90af2f4 (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
Distribution Mean apparent volume of distribution (V d ) for mesna is 0.652 ± 0.242 L/kg after intravenous administration which suggests distribution to total body water (plasma, extracellular fluid, and intracellular water).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef161ede-0451-43c8-b0e5-cb108b138e38 (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
Distribution Mean apparent volume of distribution (V d ) for mesna is 0.652 ± 0.242 L/kg after intravenous administration which suggests distribution to total body water (plasma, extracellular fluid, and intracellular water).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49e9c804-9e88-4774-8faf-35bd61b3a8e9 (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
Distribution Mean apparent volume of distribution (V d ) for mesna is 0.652 ± 0.242 L/kg after intravenous administration which suggests distribution to total body water (plasma, extracellular fluid, and intracellular water).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a51ffdb-f59f-4e02-b3c4-f3457ab7b514 (opens source in a new tab)
Mesna label
Version not recorded · Effective date not recorded
Distribution Mean apparent volume of distribution (V d ) for mesna is 0.652 ± 0.242 L/kg after intravenous administration which suggests distribution to total body water (plasma, extracellular fluid, and intracellular water).
Projected row 950
- Medicine slug
- metaxalone
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 58
- Source count
- 57
- Agreement rate
- 0.578947
- Recorded readings
11.1 hours
- Numeric value
- 11.1
- Unit
- hours
- Source records
- 33
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 33 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c91c0fb0-0b61-4e45-8bea-d0bf57ca7068 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b21a974-6a5a-9efb-e9de-470363217126 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2b46d69-1c20-5ae9-e053-2a95a90a60a9 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c3ae824-48a9-fd91-e063-6394a90a9a54 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4a0e910-2b20-46d4-b49e-21fb15925b58 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9e45029-b1a4-435f-b9ca-cdfa01051bc8 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45726fbc-3450-63f7-e063-6394a90a671a (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f06f2b96-3684-483c-89f7-6c9201fd4664 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a12304b7-6477-4518-8db5-898879c62caf (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a7c8b4d-7add-cb31-e063-6294a90a37f8 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c3b2aa4-fe65-507c-e063-6394a90a7b00 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe82b33b-2a24-4477-91ca-b23e59156675 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a662fd07-2896-4cbb-bafc-aa5ab179a148 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c1e10fe-0330-4bf8-a94d-aeed80f6aef1 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1cef46bb-e590-4a58-82e0-7cf1fc3836a5 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3a4f6bc-abd4-4b8e-970f-59b3aa6f17a0 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e7efad7-2752-4f7d-ba30-40f17d13e4c3 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1541da6a-7681-40bc-b67e-28e02a950d72 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5de36266-3964-5aca-e053-2991aa0a2205 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fba1601d-3ac4-41cf-9548-35ec4994a95e (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3aa9dba9-29b0-4520-a0f7-66d19d52c6bc (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:413b300d-4163-afef-e063-6394a90a618f (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5bcdc9d3-8827-4d05-8783-4519f1b284a3 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4caa7c6-afb5-43a2-ba38-cf30106b1d62 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de3448df-4ca1-44ec-bad1-486549cddf64 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c86862a4-f6ff-4268-bec6-35dedbe4cd4a (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4facde6f-1828-9138-e063-6294a90a1ec1 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02eb5938-cd59-4a81-853d-a4148d813a94 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9cefc55-7643-ce9b-e053-2a95a90aff12 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:edc6ba8d-2d45-4833-8dc7-e2d4e5d72856 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36c1d263-48ce-831b-e063-6394a90a0a2b (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8294bb3c-c8eb-474c-b567-e53cf81249e9 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a23ca660-b066-1396-e053-2a95a90a30b2 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The mean half-life was 11.1 hours in females and 7.6 hours in males.
9.0 ± 4.8 hours
- Numeric value
- 9
- Unit
- hours
- Source records
- 23
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 23 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd1c9022-aadc-af1f-e053-2995a90a0b42 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 ± 4.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c796d4a1-fad4-4a0c-a459-8ae3b5b52fb6 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 ± 4.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f758053-2367-4c5f-9bbd-ce8ce263a615 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 ± 4.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3279496-293e-7e1f-e053-2a95a90ab506 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 ± 4.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1f49112-e8ce-43a9-bdb8-1a3db4fb6bc4 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 ± 4.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c3bc0a2-5c93-e1d6-e053-2995a90a0b83 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 ± 4.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01199953-8124-4ace-947f-7b11989b44c3 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 ± 4.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee86f52c-fbf4-4882-bb7d-50220736fbb3 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 ± 4.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b7b4fc3-3f38-db66-e053-2995a90aaadb (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 ± 4.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91432cd0-8404-8029-e053-2a95a90adc1b (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 ± 4.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a558a2f-f9be-40d1-8d02-dd0c8c501ef6 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 ± 4.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d0276e7b-a1c9-61f3-e053-2a95a90ae3aa (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 ± 4.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f05bb280-6736-4215-be5b-0e5f7991cd87 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 ± 4.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87518046-c959-d5f3-e053-2a95a90a5f7e (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 ± 4.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c7d0cd4-625a-485e-9d13-ce854630148c (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 ± 4.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef47682d-ea41-465e-aa21-cc773d45a6f0 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 ± 4.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c2dd7071-cba3-410c-ade5-9d7e5af42038 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 ± 4.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07ccff59-e335-40be-9e40-fd2d08197617 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 ± 4.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49250bbf-fbfe-07cd-e054-00144ff88e88 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 ± 4.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02c42f72-5d78-436d-8105-8c0f8d4c0d91 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 ± 4.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6afb4d3-eb3e-4e9f-9aa9-a44cfacb959c (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 ± 4.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b713a0f2-d47a-0ae7-e053-2995a90a5b85 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 ± 4.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8aa84e64-0075-4f22-a576-da085f32d56c (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
Thereafter, metaxalone concentrations decline log-linearly with a terminal half-life of 9.0 ± 4.8 hours.
5 hours
- Numeric value
- 5
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc6de1a6-26aa-47ac-a5d2-bf127a6ca563 (opens source in a new tab)
Metaxalone label
Version not recorded · Effective date not recorded
The plasma half-life in adult healthy subjects was approximately 5 hours after administration of Metaxalone Tablets, 640 mg.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=940Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.